Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | NGS for KD mutational analysis in CML patients on TKIs

Hugues de Lavallade • 7 Dec 2019
ASH 2019
Chronic Myeloid Leukemia Leukemia

Kinase domain mutations in the BCR-ABL1 gene are associated with resistance to tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML). Hugues de Lavallade, MD, PhD, King’s College London, London, UK, discusses the interim analysis of a prospective non-interventional study (NCT03647215) of centralized next-generation sequencing (NGS) screening to detect kinase domain mutations, in order to evaluate the use of NGS in clinical practice. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Hugues de Lavallade

1:37
NGS can detect low level KD mutations in CP-CML patients
Hugues de Lavallade • 7 Dec 2019
1:54
ddPCR for rapid screening of actionable KD mutations in CML
Hugues de Lavallade • 7 Dec 2019

Related Videos

3:05
The development of iNKT-CAR T-cells for hematological malignancies
Kanagaraju Ponnusamy • 29 Apr 2024
2:00
BTK degraders in CLL and lymphoma: a Phase I trial of NX-5948
Dima El-Sharkawi • 28 Apr 2024
2:04
Increasing awareness of germline predispositions to hematological malignancies in pediatric patients
Anupama Rao • 29 Apr 2024
0:57
The development of a UK AML registry
Priyanka Mehta • 22 Apr 2024
The content of VJHemOnc is intended for healthcare professionals